Medical Condition News

RSS

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

SynCardia Systems and AorTech International sign technology license agreement

On Sept. 22, SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary CardioWest™ Total Artificial Heart, announced an exclusive technology licensing agreement with AorTech International plc (AIM: AOR).

23 Sep 2009

Melanoma patients could be spared from unnecessary surgery

Researchers have shown for the first time that patterns of ultrasound signals can be used to identify whether or not cancer has started to spread in melanoma patients, and to what extent. The discovery enables doctors to decide on how much surgery, if any, is required and to predict the patient's probable survival.

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin on Thursday.

23 Sep 2009

NIST collaborates with private industry to release a new reference material for beryllium

Researchers at the National Institute of Standards and Technology (NIST), in collaboration with private industry and other government agencies, have produced a new reference material for beryllium. Beryllium, an exotic rare-earth metal used as a hardener in high-performance alloys and ceramics, can cause berylliosis-a chronic, incurable and sometimes fatal illness.

23 Sep 2009

Spread of cancer in melanoma patients can be determined by ultrasound signals

23 Sep 2009

MMI to provide sign language interpreters for deaf or hard-of-hearing patients

Under a voluntary resolution agreement reached with the U.S. Department of Health and Human Services (HHS), deaf or hard-of-hearing patients at the Mid-Maryland Musculoskeletal Institute (MMI) of Frederick, Md., will be screened and provided with sign language interpreters whenever interpreter services are necessary for effective communication. MMI is an 11-physician orthopedic practice with offices in Frederick and Hagerstown, Md., serving approximately 1,000 patients per month.

23 Sep 2009

Autism Treatment Center of America announces Son-Rise Program lecture dates

Raun K.Kaufman, CEO of the Autism Treatment Center of America and Advisory Board Member of the United States Autism & Asperger's Association (USAAA), announces a series of lecture dates to be held this autumn in the UK. The Son-Rise Program of the Autism Treatment Center of America has assisted parents worldwide and in the UK dealing with Autism Spectrum Disorders including Alison Taylor.

23 Sep 2009

Leading oncology experts to discuss management of hematological malignancies

Oncology experts from leading cancer organizations from around the country, including the John Theurer Cancer Center, MD Anderson Cancer Center, the Mayo Clinic, Dana Farber Cancer Institute and the National Cancer Institute, will discuss trends in patient care, novel therapies through clinical trials and emerging concepts in the management of hematological malignancies.

23 Sep 2009

There is no evidence to support the use of any test for ovarian cancer: NBOCC

In an Australian first, leading experts and organizations have agreed a position statement on screening for ovarian cancer, Australia's leading cause of death from gynecological malignancy.

23 Sep 2009

ESMO recognises 27 cancer centers for their excellent palliative care

The European Society for Medical Oncology is proud to announce that it has formally recognized 27 cancer centers for their commitment to providing excellent palliative care as part of the care they offer to patients.

23 Sep 2009

Ninety per cent of older persons in rural Bangladesh malnourished: Study

Ninety per cent of older persons in rural Bangladesh displayed either overt or risk for malnutrition in a collaborative study presented in a dissertation by Tamanna Ferdous from Uppsala University Sept 22, 2009. The results, which are part of a larger international study, challenge the Millenium Development Goals.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Preventing nerve cell death in diabetics

Dennis Paul, PhD, Associate Professor of Pharmacology, and Harry Gould, MD, PhD, the Tom Benson Professor of Neurology at LSU Health Sciences Center New Orleans, have been awarded one of two scientific research grants made in 2009 by The Neuropathy Association. The $80,000 grant will fund research to learn how to prevent nerve cell death in people with uncontrolled or untreated diabetes resulting in neuropathy.

23 Sep 2009

Breast cancer awareness campaign launched by Samsung Electronics Europe

Samsung Electronics Europe has launched ‘Everybody’s Doing It’, an online campaign and website which is a call to action encouraging women in Europe to check for breast cancer and prevent the disease from spreading. By visiting www.morethantalk.eu women can find an instant community of support, a place to make pledges to raise further awareness and a place to view or forward a short viral movie called ‘Everybody’s Doing It’; containing footage of eight women whose lives have been affected by breast cancer. The viral is intended to reach over 400,000 women - more than the number who are diagnosed with breast cancer in Europe every year.

23 Sep 2009

Exercise counseling and fitness center training effective for type 2 diabetic patients

Physical therapist-directed exercise counseling combined with fitness center-based exercise training can improve muscular strength and exercise capacity in people with type 2 diabetes, with outcomes similar to those of supervised exercise, according to a randomized clinical trial published in the September issue of Physical Therapy, the scientific journal of the American Physical Therapy Association (APTA).

23 Sep 2009

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

Professional and personal distress levels high in primary care physicians

Primary care physicians who participated in an educational program that included an emphasis on mindful communication reported improvement in personal well-being, emotional exhaustion, empathy and attitudes associated with patient-centered care, according to a study in the September 23/30 issue of JAMA, a theme issue on medical education.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

New method to diagnose active tuberculosis

Active tuberculosis can be rapidly identified in patients with negative sputum tests by a new method, according to European researchers. Active tuberculosis (TB) is the seventh-leading cause of death worldwide, and while the diagnosis of active TB can be rapidly established when the bacteria can be identified on sputum microscopy, in about half of all cases, the TB bacterium cannot be detected, making another diagnostic option critical in efforts to control the spread of TB.

23 Sep 2009